The epidemiologic, clinical, and economic value of a universal coronavirus disease 2019 (COVID-19) vaccine.
FDA rejects Checkpoint Therapeutics’ PD-L1 drug cosibelimab over manufacturing issues
Checkpoint Therapeutics’ anti-PD-L1 antibody has been turned down by the FDA due to manufacturing issues, sending its share price down 45% premarket on Monday. The